drugset
drugset / Trial / NCT04674748

To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550

NCT04674748 ↗

Phase 1 Terminated 3 enrolled Incyte Biosciences Japan GK
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the safety, tolerability, and PK of INCB086550 and determine the Maximum Tolerated Dose (MTD) and/or recommended Phase 2 Dose(RP2D) of INCB086550, whichever is lower, in Japanese participants with advanced solid tumors.

Timeline

Start
2021-02-03
Primary completion
2022-05-13
Completion
2022-05-13

Outcome

Outcome not reported

Stopped (Business): “The study was terminated early due to a business decision.”

Drugs

EvaluationDrugModalityDoseRoute
Subject INCB086550 Small molecule — —

Indications

cancer